HOME >> MEDICINE >> NEWS
Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration

NEW ORLEANS, October 21, 2004 -- Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) today announced that the treatment effect with the investigational drug Macugen (pegaptanib sodium injection) extends for two years in patients with neovascular or wet, age-related macular degeneration (AMD), who are at risk of losing their vision. A treatment benefit was also seen for patients who received Macugen for two years compared to those only receiving one year of therapy.

The data confirm that patients benefit from two years of treatment with Macugen for wet AMD. The second year data for Macugen will be presented by Anthony P. Adamis, M.D., Chief Scientific Officer, Eyetech Pharmaceuticals and Steven Schwartz, M.D., Chief, Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, at the Retina Subspecialty symposium of the American Academy of Ophthalmology Meeting on Friday, October 22, 2004 at 8:00 a.m. Central Time and 10:38 a.m. Central Time respectively.

Eyetech and Pfizer are partnering to develop and market Macugen, a treatment for neovascular or wet AMD, the leading cause of severe vision loss in patients older than 50 years of age in the developed world. Eyetech and Pfizer have filed an NDA for Macugen for neovascular AMD with the FDA. Macugen has been assigned priority review status and the PDUFA date is December 17, 2004.

"We are excited about the new data because they confirm that treatment with Macugen is effective in patients with neovascular AMD who are at risk of losing their vision," said David R. Guyer, M.D., Chief Executive Officer, Eyetech Pharmaceuticals. "The two year data on Macugen demonstrate that longer term use may be beneficial for patients suffering from this chronic disease."

These data are from two, pivotal Phase II/III randomized, multi-center, double-masked studies in patients with all subtypes of neovascular AMD. 1,186 patients were initially randomized to receive one
'"/>


21-Oct-2004


Page: 1 2 3

Related medicine news :

1. The Gerontological Society of America announces Hartford Fellowship recipients
2. TB Alliance announces new drug discovery program with GlaxoSmithKline
3. ASGE announces grant recipients in annual research awards program
4. Novartis announces collaboration with Bayer for EMSELEX
5. American College of Chest Physicians announces new Critical Care Institute
6. Department of Energy announces new agreement with USC, national labs and private company
7. ACP announces international medical fellowship
8. St. Jude Medical announces CRT patients showed improvement in the RHYTHM ICD study
9. St. Jude Medical announces PAVE and DINAMIT clinical trial results
10. National Inventors Hall of Fame announces 2004 class of inventors
11. Joslin announces first international affiliate in Bahrain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... February 19, 2019 , ... ... stigma in pregnant and postpartum women, a team led by a Worcester Polytechnic ... postpartum often show increased depressive symptoms, greater weight gain during pregnancy, and weight ...
(Date:2/19/2019)... ... February 19, 2019 , ... Landscape Structures Inc., a Delano, Minn.-based commercial ... to be a stunning and fun addition to any play space. Spinning is one ... Curva™ Spinners will provide kids’ brains with valuable equilibrium information. , Whether park and ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... experience to The Oncology Institute of Hope and Innovation. , Dr. Lombardi completed ... cum laude. He received his medical degree from the University of Rochester School ...
(Date:2/19/2019)... ... February 19, 2019 , ... ClearHealth ... to Foley & Lardner LLP, as Recognized Consultants. The CHQI Recognized Consultant Program ... in pursuing CHQI accreditation. , Ms. Wein and Mr. Einhorn are part ...
(Date:2/19/2019)... Fla. (PRWEB) , ... February 18, 2019 , ... ... in the nation to test the PathO3Gen Solutions Footwear Sanitizing Stations to maximize ... Solestice 3/15 TechnologyTM to kill superbugs such as MRSA and C. difficile, which ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... (PRWEB) , ... February 19, ... ... and infrastructure solutions provider for global service providers, enterprises, and developers, announced ... orchestration platform with the Arvizio MR Studio mixed reality visualization and collaboration ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... for Stage IV metastatic breast cancer (MBC), announces the opening of the 2019 ... Fairchild, “In honor of our 10-year anniversary, we are excited to announce we ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... completed his new book “Live Hard Die Young.” Dr. Oexner was the first ... medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a supervisor on ...
Breaking Medicine Technology:
Cached News: